Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients

 – Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options –

– Represents Immuneering’s fourth agreement with a pharma partner –

– Further expands external partnerships to bring innovative new combinations to patients –
 

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (NASDAQ:IMRX) today announced it has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. (TSE: 4503). Under the agreement, Immuneering will supply its investigational MEK inhibitor, atebimetinib, for two Astellas-sponsored studies targeting the subset of pancreatic cancer patients whose tumors express CLDN18.2. One trial will evaluate an Astellas investigational CLDN18.2-targeted program added to atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patients. A second trial will evaluate a chemotherapy-free regimen combining a different Astellas investigational CLDN18.2-targeted program with atebimetinib in previously-treated metastatic pancreatic cancer patients. Further trial details will be forthcoming.